LOXL2 small molecule inhibitor restrains malignant transformation of cervical cancer cells by repressing LOXL2-induced epithelial-mesenchymal transition (EMT)

References

• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.
   PubMed Web of Science ®Google Scholar
• Vu M, Yu J, Awolude OA, et al. Cervical cancer worldwide. Curr Probl Cancer. 2018;42:457–465.
   PubMed Web of Science ®Google Scholar
• Scarth JA, Patterson MR, Morgan EL, et al. The human papillomavirus oncoproteins: a review of the host pathways targeted on the road to transformation. J Gen Virol. 2021;102:001540.
   PubMed Web of Science ®Google Scholar
• Leechanachai P, Banks L, Moreau F, et al. The E5 gene from human papillomavirus type 16 is an oncogene which enhances growth factor-mediated signal transduction to the nucleus. Oncogene. 1992;7:19–25.
   PubMed Web of Science ®Google Scholar
• Scheffner M, Werness BA, Huibregtse JM, et al. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell. 1990;63:1129–1136.
   PubMed Web of Science ®Google Scholar
• White EA, Münger K, Howley PM. High-risk human papillomavirus E7 proteins target PTPN14 for degradation. mBio. 2016;7. DOI:10.1128/mBio.01530-16
   Web of Science ®Google Scholar
• James CD, Fontan CT, Otoa R, et al. Human papillomavirus 16 E6 and E7 synergistically repress innate immune gene transcription. mSphere. 2020;5. DOI:10.1128/mSphere.00828-19
   Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA: a cancer. J Clinicians. 2020;70:7–30.
   PubMed Web of Science ®Google Scholar
• Tsikouras P, Zervoudis S, Manav B, et al. Cervical cancer: screening, diagnosis and staging. J buon. 2016;21:320–325.
   PubMed Web of Science ®Google Scholar
• Wimberly H, Brown JR, Schalper K, et al. PD-L1 expression correlates with tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy in breast cancer. Cancer Immunol Res. 2015;3:326–332.
   PubMed Web of Science ®Google Scholar
• Saglam O, Conejo-Garcia J. PD-1/PD-L1 immune checkpoint inhibitors in advanced cervical cancer. Integr Cancer Sci Ther. 2018;5. DOI:10.15761/ICST.1000272
   PubMedGoogle Scholar
• Wang Y, Li G. PD-1/PD-L1 blockade in cervical cancer: current studies and perspectives. Front Med. 2019;13:438–450.
   PubMed Web of Science ®Google Scholar
• Vallet SD, Ricard-Blum S. Lysyl oxidases: from enzyme activity to extracellular matrix cross-links. Essays in Biochemistry. 2019;63:349–364.
   PubMed Web of Science ®Google Scholar
• Shah MA, Scaman CH, Palcic MM, et al. Kinetics and stereospecificity of the lysyl oxidase reaction. J Biol Chem. 1993;268:11573–11579.
   PubMed Web of Science ®Google Scholar
• Williamson PR, Kagan HM. Reaction pathway of bovine aortic lysyl oxidase. J Biol Chem. 1986;261:9477–9482.
   PubMed Web of Science ®Google Scholar
• López B, González A, Hermida N, et al. Role of lysyl oxidase in myocardial fibrosis: from basic science to clinical aspects. Am J Physiol Heart Circ Physiol. 2010;299:H1–9.
   PubMed Web of Science ®Google Scholar
• Zibadi S, Vazquez R, Larson DF, et al. T lymphocyte regulation of lysyl oxidase in diet-induced cardiac fibrosis. Cardiovasc Toxicol. 2010;10:190–198.
   PubMed Web of Science ®Google Scholar
• Soares MB, de Lima Rs, Rocha LL, et al. Gene expression changes associated with myocarditis and fibrosis in hearts of mice with chronic chagasic cardiomyopathy. J Infect Dis. 2010;202:416–426.
   PubMed Web of Science ®Google Scholar
• Payne SL, Hendrix MJ, Kirschmann DA. Paradoxical roles for lysyl oxidases in cancer–a prospect. J Cell Biochem. 2007;101:1338–1354.
   PubMed Web of Science ®Google Scholar
• Finney J, Moon HJ, Ronnebaum T, et al. Human copper-dependent amine oxidases. Arch Biochem Biophys. 2014;546:19–32.
   PubMed Web of Science ®Google Scholar
• Chung CH, Parker JS, Ely K, et al. Gene expression profiles identify epithelial-to-mesenchymal transition and activation of nuclear factor-kappaB signaling as characteristics of a high-risk head and neck squamous cell carcinoma. Cancer Res. 2006;66:8210–8218.
   PubMed Web of Science ®Google Scholar
• Barry-Hamilton V, Spangler R, Marshall D, et al. Allosteric inhibition of lysyl oxidase-like-2 impedes the development of a pathologic microenvironment. Nat Med. 2010;16:1009–1017.
   PubMed Web of Science ®Google Scholar
• Fong SF, Dietzsch E, Fong KS, et al. Lysyl oxidase-like 2 expression is increased in colon and esophageal tumors and associated with less differentiated colon tumors. Genes Chromosomes Cancer. 2007;46:644–655.
   PubMed Web of Science ®Google Scholar
• Akiri G, Sabo E, Dafni H, et al. Lysyl oxidase-related protein-1 promotes tumor fibrosis and tumor progression in vivo. Cancer Res. 2003;63:1657–1666.
   PubMed Web of Science ®Google Scholar
• Mahjour F, Dambal V, Shrestha N, et al. Mechanism for oral tumor cell lysyl oxidase like-2 in cancer development: synergy with PDGF-AB. 2019;8:34.
   Google Scholar
• Peng L, Ran YL, Hu H, et al. Secreted LOXL2 is a novel therapeutic target that promotes gastric cancer metastasis via the Src/FAK pathway. Carcinogenesis. 2009;30:1660–1669.
   PubMed Web of Science ®Google Scholar
• Rhodes DRK-S-S, Mahavisno V, Varambally R, et al. Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. Neoplasia. 2007;9:166–180.
   Google Scholar
• Cerami E, Gao J, Dogrusoz U, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2:401–404.
   PubMed Web of Science ®Google Scholar
• Forbes SA, Beare D, Boutselakis H, et al. COSMIC: somatic cancer genetics at high-resolution. Nucleic Acids Res. 2017;45:D777–d83.
   PubMed Web of Science ®Google Scholar
• Forbes SA, Beare D, Gunasekaran P, et al. COSMIC: exploring the world’s knowledge of somatic mutations in human cancer. Nucleic Acids Res. 2014;43:D805–D11.
   PubMed Web of Science ®Google Scholar
• Lánczky A, Nagy Á, Bottai G, et al. miRpower: a web-tool to validate survival-associated miRNAs utilizing expression data from 2178 breast cancer patients. Breast Cancer Res Treat. 2016;160:439–446.
   PubMed Web of Science ®Google Scholar
• Rhodes DR, Yu J, Shanker K, et al. ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia. 2004;6:1–6.
   PubMed Web of Science ®Google Scholar
• Pathan M, Keerthikumar S, Ang CS, et al. FunRich: an open access standalone functional enrichment and interaction network analysis tool. Proteomics. 2015;15:2597–2601.
   PubMed Web of Science ®Google Scholar
• Vasaikar SV, Straub P, Wang J, et al. LinkedOmics: analyzing multi-omics data within and across 32 cancer types. Nucleic Acids Res. 2017;46:D956–D63.
   Web of Science ®Google Scholar
• Hutchinson JH, Rowbottom MW, Lonergan D, et al. Small molecule lysyl oxidase-like 2 (LOXL2) inhibitors: the identification of an inhibitor selective for LOXL2 over LOX. ACS Med Chem Lett. 2017;8:423–427.
   PubMed Web of Science ®Google Scholar
• Cao C, Lin S, Zhi W, et al. LOXL2 expression status is correlated with molecular characterizations of cervical carcinoma and associated with poor cancer survival via epithelial-mesenchymal transition (EMT) phenotype. Front Oncol. 2020;10:284.
   PubMed Web of Science ®Google Scholar
• Nieto MA, Huang RY, Jackson RA, et al. EMT: 2016. Cell. 2016;166:21–45.
   PubMed Web of Science ®Google Scholar
• Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest. 2009;119:1420–1428.
   PubMed Web of Science ®Google Scholar
• Saitoh M. Involvement of partial EMT in cancer progression. J Biochem. 2018;164:257–264.
   PubMed Web of Science ®Google Scholar
• Lim J, Thiery JP. Epithelial-mesenchymal transitions: insights from development. Development. 2012;139:3471–3486.
   PubMed Web of Science ®Google Scholar
• Shibue T, Weinberg RA. EMT, CSCs, and drug resistance: the mechanistic link and clinical implications. Nat Rev Clin Oncol. 2017;14:611–629.
   PubMed Web of Science ®Google Scholar
• Jolly MK, Ware KE, Gilja S, et al. EMT and MET: necessary or permissive for metastasis? Mol Oncol. 2017;11:755–769.
   PubMed Web of Science ®Google Scholar
• Hugo H, Ackland ML, Blick T, et al. Epithelial–mesenchymal and mesenchymal–epithelial transitions in carcinoma progression. J Cell Physiol. 2007;213:374–383.
   PubMed Web of Science ®Google Scholar
• Yang J, Weinberg RA. Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev Cell. 2008;14:818–829.
   PubMed Web of Science ®Google Scholar
• De Craene B, Berx G. Regulatory networks defining EMT during cancer initiation and progression. Nat Rev Cancer. 2013;13:97–110.
   PubMed Web of Science ®Google Scholar
• Du B, Shim JS. Targeting Epithelial-Mesenchymal Transition (EMT) to overcome drug resistance in cancer. Molecules. 2016;21:965.
   PubMed Web of Science ®Google Scholar
• Zheng X, Carstens JL, Kim J, et al. Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer. Nature. 2015;527:525–530.
   PubMed Web of Science ®Google Scholar
• McConkey DJ, Choi W, Marquis L, et al. Role of epithelial-to-mesenchymal transition (EMT) in drug sensitivity and metastasis in bladder cancer. Cancer Metastasis Rev. 2009;28:335–344.
   PubMed Web of Science ®Google Scholar
• Huang J, Li H, Ren G. Epithelial-mesenchymal transition and drug resistance in breast cancer (Review). Int J Oncol. 2015;47:840–848.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Liang C, Xue F, et al. Salinomycin decreases doxorubicin resistance in hepatocellular carcinoma cells by inhibiting the β-catenin/TCF complex association via FOXO3a activation. Oncotarget. 2015;6:10350–10365.
   PubMedGoogle Scholar
• Toden S, Okugawa Y, Jascur T, et al. Curcumin mediates chemosensitization to 5-fluorouracil through miRNA-induced suppression of epithelial-to-mesenchymal transition in chemoresistant colorectal cancer. Carcinogenesis. 2015;36:355–367.
   PubMed Web of Science ®Google Scholar
• Luna AJ, Sterk RT, Griego-Fisher AM, et al. MEK/ERK signaling is a critical regulator of high-risk human papillomavirus oncogene expression revealing therapeutic targets for HPV-induced tumors. PLoS Pathog. 2021;17:e1009216.
   PubMed Web of Science ®Google Scholar
• Morgan EL, Scarth JA, Patterson MR, et al. E6-mediated activation of JNK drives EGFR signalling to promote proliferation and viral oncoprotein expression in cervical cancer. Cell Death Differ. 2021;28:1669–1687.
   PubMed Web of Science ®Google Scholar
• Morgan EL, Macdonald A, Galloway DA. Autocrine STAT3 activation in HPV positive cervical cancer through a virus-driven Rac1-NFκB-IL-6 signalling axis. PLoS Pathog. 2019;15:e1007835.
   PubMed Web of Science ®Google Scholar
• Zhang E, Feng X, Liu F, et al. Roles of PI3K/Akt and c-Jun signaling pathways in human papillomavirus type 16 oncoprotein-induced HIF-1α, VEGF, and IL-8 expression and in vitro angiogenesis in non-small cell lung cancer cells. PLoS One. 2014;9:e103440.
   PubMed Web of Science ®Google Scholar
• Matsuoka K, Bakiri L, Wolff LI, et al. Wnt signaling and Loxl2 promote aggressive osteosarcoma. Cell Res. 2020;30:885–901.
   PubMed Web of Science ®Google Scholar
• Wang M, Zhao X, Zhu D, et al. HIF-1α promoted vasculogenic mimicry formation in hepatocellular carcinoma through LOXL2 up-regulation in hypoxic tumor microenvironment. J Exp Clin Cancer Res. 2017;36:60.
   PubMed Web of Science ®Google Scholar